{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:11:13Z","timestamp":1792789873539,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":45,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.semnephrol.2024.151517","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T01:39:11Z","timestamp":1715650751000},"page":"151517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oral Anticoagulation Use in Individuals With Atrial Fibrillation and Chronic Kidney Disease: A Review"],"prefix":"10.1016","volume":"44","author":[{"given":"Sara L.","family":"Wing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Mavrakanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziv","family":"Harel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2024.151517_bib0001","doi-asserted-by":"crossref","first-page":"49","DOI":"10.15420\/ecr.2016:13:2","article-title":"Atrial fibrillation, cognitive decline and dementia","volume":"11","author":"Alonso","year":"2016","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.semnephrol.2024.151517_bib0002","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2024.151517_bib0003","doi-asserted-by":"crossref","first-page":"i4482","DOI":"10.1136\/bmj.i4482","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","journal-title":"BMJ."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0004","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028496","article-title":"Association of chronic kidney disease with atrial fibrillation in the general adult population: a nationwide population-based study","volume":"12","author":"Kim","year":"2023","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0005","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.kint.2017.11.019","article-title":"Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle","volume":"93","author":"Roy-Chaudhury","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0006","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/clc.23196","article-title":"Anticoagulation in chronic kidney disease: from guidelines to clinical practice","volume":"42","author":"Aursulesei","year":"2019","journal-title":"Clin Cardiol."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0007","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/phar.2350","article-title":"Oral anticoagulant prescription trends, profile use, and determinants of adherence in patients with atrial fibrillation","volume":"40","author":"Perreault","year":"2020","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0008","doi-asserted-by":"crossref","first-page":"40","DOI":"10.15420\/ecr.2017:11:2","article-title":"Direct oral anticoagulants: a quick guide","volume":"12","author":"Julia","year":"2017","journal-title":"Eur Cardiol."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0009","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0010","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0011","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0012","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/10742484221142220","article-title":"Prescribing patterns of direct-acting oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: a retrospective cohort analysis","volume":"27","author":"Reyes","year":"2022","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0014","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct oral anticoagulants versus warfarin across the spectrum of kidney function: patient-level network meta-analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacc.2019.10.059","article-title":"Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis","volume":"75","author":"Kuno","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.semnephrol.2024.151517_bib52","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.2215\/CJN.04550511","article-title":"Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation","volume":"6","author":"Winkelmayer","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2024.151517_bib53","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2024.151517_bib0016","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0017","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0018","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1681\/ASN.2013040361","article-title":"Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD","volume":"25","author":"Harel","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0019","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/M19-0087","article-title":"Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis","volume":"171","author":"Ha","year":"2019","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0020","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2022.1292","article-title":"Efficacy and safety considerations with dose-reduced direct oral anticoagulants: a review","volume":"7","author":"Bikdeli","year":"2022","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0023","unstructured":"Bristol Myers Squibb. Eliquis product monograph. 2019. Available from: https:\/\/www.bms.com\/assets\/bms\/ca\/documents\/productmonograph\/ELIQUIS_EN_PM.pdf. Accessed December 23, 2023"},{"key":"10.1016\/j.semnephrol.2024.151517_bib0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0022","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0024","unstructured":"Boehringer Ingelheim Canada Ltd. Dabigatran etexilate product monograph. 2017. Updated March 23, 2020. Available from: https:\/\/www.boehringer-ingelheim.com\/ca\/bipdf\/pradaxa-product-monographAccess date: December 23, 2023"},{"key":"10.1016\/j.semnephrol.2024.151517_bib0021","unstructured":"Bayer. Product monograph including patient medication information: Xarelto. Updated April 17, 2023. Available from: https:\/\/www.bayer.com\/sites\/default\/files\/2020-11\/xarelto-pm-en.pdf. Accessed December 23, 2023."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0026","first-page":"e1","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0027","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","article-title":"The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0028","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0029","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0030","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/ehjqcco\/qcac069","article-title":"Kidney function and the comparative effectiveness and safety of direct oral anticoagulants vs. warfarin in adults with atrial fibrillation: a multicenter observational study","volume":"9","author":"Jun","year":"2023","journal-title":"Eur Heart J Qual Care Clin Outcomes."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100675","article-title":"Safety and effectiveness of rivaroxaban versus warfarin across GFR levels in atrial fibrillation: a population-based study in Australia and Canada","volume":"5","author":"Ha","year":"2023","journal-title":"Kidney Med."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0032","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.006515","article-title":"Comparative effectiveness and safety of oral anticoagulants across kidney function in patients with atrial fibrillation","volume":"13","author":"Yao","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2020.01.010","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease","volume":"223","author":"Weir","year":"2020","journal-title":"Am Heart J."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0034","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ckj\/sfad004","article-title":"Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D","volume":"16","author":"Welander","year":"2023","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0051","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/j.ajkd.2023.08.017","article-title":"Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: nationwide US cohort study","volume":"83","author":"Fu","year":"2024","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000535546","article-title":"Anticoagulation in patients with chronic kidney disease","volume":"55","author":"Elenjickal","year":"2024","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0036","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2215\/CJN.02170218","article-title":"Clinical pharmacology of oral anticoagulants in patients with kidney disease","volume":"14","author":"Jain","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0037","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/CIRCULATIONAHA.123.065614","article-title":"Associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease","volume":"148","author":"Xu","year":"2023","journal-title":"Circulation."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0038","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0039","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cjca.2017.02.004","article-title":"Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta-analysis","volume":"33","author":"Harel","year":"2017","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0040","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/ki.2009.477","article-title":"Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy","volume":"77","author":"Wizemann","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0041","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1046\/j.1523-1755.2003.00101.x","article-title":"Elevated risk of stroke among patients with end-stage renal disease","volume":"64","author":"Seliger","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0042","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40697-014-0021-x","article-title":"The three-year incidence of major hemorrhage among older adults initiating chronic dialysis","volume":"1","author":"Sood","year":"2014","journal-title":"Can J Kidney Health Dis."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0043","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.115.018294","article-title":"Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation: a competing-risk analysis of a nationwide cohort","volume":"133","author":"Shih","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0044","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2175","article-title":"Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis","volume":"3","author":"Randhawa","year":"2020","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0045","doi-asserted-by":"crossref","DOI":"10.1007\/s11255-023-03889-3","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation on chronic hemodialysis: a meta-analysis of randomized controlled trials","author":"Navalha","year":"2023","journal-title":"Int Urol Nephrol."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0046","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0047","series-title":"Strategies for the Management of Atrial Fibrillation in Patients Receiving Dialysis (SAFE-D)","author":"Harel","year":"2023"},{"key":"10.1016\/j.semnephrol.2024.151517_bib0048","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jtcvs.2019.02.061","article-title":"Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis","volume":"159","author":"Havers-Borgersen","year":"2020","journal-title":"J Thorac Cardiovasc Surg."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0049","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.ajkd.2015.01.022","article-title":"Dose-finding study of rivaroxaban in hemodialysis patients","volume":"66","author":"De Vriese","year":"2015","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.semnephrol.2024.151517_bib0050","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.2169\/internalmedicine.0021-17","article-title":"Atrial fibrillation had less impact on the risk of ischemic stroke in non-anticoagulated patients undergoing hemodialysis: insight from the RAKUEN study","volume":"57","author":"Mitsuma","year":"2018","journal-title":"Intern Med."}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929524000378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929524000378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T10:51:49Z","timestamp":1748343109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929524000378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0270929524000378"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2024.151517","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Anticoagulation Use in Individuals With Atrial Fibrillation and Chronic Kidney Disease: A Review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2024.151517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151517"}}